DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
SECAUCUS, N.J. , June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
![]() QDI 2 months ago | Other | €0.7 Per Share |
![]() QDI 5 months ago | Other | €0.65 Per Share |
![]() QDI 8 months ago | Other | €0.65 Per Share |
![]() QDI 11 months ago | Other | €0.65 Per Share |
![]() QDI 5 Apr 2024 | Other | €0.65 Per Share |
21 Jul 2025 (32 Days) Date | | - Cons. EPS | - EPS |
21 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | - Cons. EPS | - EPS |
22 Oct 2024 Date | | - Cons. EPS | - EPS |
24 Jul 2024 Date | | - Cons. EPS | - EPS |
![]() QDI 2 months ago | Other | €0.7 Per Share |
![]() QDI 5 months ago | Other | €0.65 Per Share |
![]() QDI 8 months ago | Other | €0.65 Per Share |
![]() QDI 11 months ago | Other | €0.65 Per Share |
![]() QDI 5 Apr 2024 | Other | €0.65 Per Share |
21 Jul 2025 (32 Days) Date | | - Cons. EPS | - EPS |
21 Apr 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | - Cons. EPS | - EPS |
22 Oct 2024 Date | | - Cons. EPS | - EPS |
24 Jul 2024 Date | | - Cons. EPS | - EPS |
Medical - Diagnostics & Research Industry | Healthcare Sector | Mr. James E. Davis CEO | XMUN Exchange | US74834L1008 ISIN |
US Country | 55,000 Employees | 7 Apr 2025 Last Dividend | 21 Jun 2005 Last Split | 17 Dec 1996 IPO Date |
Quest Diagnostics Incorporated, established in 1967 and based in Secaucus, New Jersey, is a prominent provider of diagnostic testing, information, and services both in the United States and internationally. The company operates with the mission to deliver critical diagnostic insights that lead to informed healthcare decisions. Using its extensive network of laboratories, patient service centers, and healthcare professionals, Quest Diagnostics offers a wide range of diagnostic information services. These services cater to a diverse clientele including physicians, hospitals, patients, health plans, government agencies, employers, and pharmaceutical companies. Through its flagship Quest Diagnostics brand and others such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, the company aims to improve health outcomes by making better information available to the healthcare ecosystem.
These encompass routine and non-routine clinical tests, advanced clinical testing, and anatomic pathology testing. Quest Diagnostics utilizes a vast array of technological platforms to provide critical diagnostic information that supports disease prevention, diagnosis, treatment, and management.
Quest Diagnostics provides comprehensive risk assessment services tailored to the needs of the life insurance sector. These services are designed to help insurance companies evaluate the health risks of policy applicants through a variety of diagnostic tests and assessments.
Offering cutting-edge information technology solutions, Quest Diagnostics helps healthcare organizations and clinicians enhance efficiency and patient care. These solutions encompass a wide range of IT services designed to facilitate the secure exchange of health information, improve lab ordering processes, and streamline patient record management.